Factbox-Bayer's new CEO: long-time Roche, Genentech executive, Bill Anderson
Reuters
Published Feb 08, 2023 19:03
LONDON (Reuters) - Bayer (ETR:BAYGN) bowed to investor pressure on Wednesday and named Bill Anderson, most recently head of Roche's pharmaceuticals business, to take over from Werner Baumann as its CEO in June.
Here are some key facts about the career about the 56-year-old American who will run the nearly 160-year-old German drugmaker:
He is a chemical engineer by education and has worked for Genentech and its parent Roche since 2006
CAREER:
1989: started his career at Ethyl Corp, a U.S.-based fuel additives company, with postings in Belgium and the Netherlands
1995: joined Raychem Corp., a U.S. technology and electronics firm
1997-2006: worked at Biogen (NASDAQ:BIIB) in the United States, UK and Ireland; roles included running its neurology unit, its largest business
2006: joined Genentech as senior vice president, immunology and ophthalmology
2010: became svp BioOncology
2013: left Genentech to become global product strategy head/chief marketing officer at Genentech's parent company, Roche
2016: returned to Genentech as head of North American operations
2017: appointed chief executive officer at Genentech
2019-2023: CEO of Roche Pharmaceutical
Sources: Roche and Bayer
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.